The Regulatory Pendulum Swings In Favor Of Antibiotics, But Will Investments Follow?
This article was originally published in Start Up
New incentives under the US government’s GAIN Act and FDA’s openness to faster development are helping put antibiotics back on investors’ radar screens, if not yet loosening their checkbooks.
You may also be interested in...
Achaogen has designed a registration program with a single Phase III study for its next-generation aminoglycoside, plazomicin, to treat serious infections due to carbapenem-resistant Enterobacteriaceae, in what could be an interesting test for potential modifications to the standard approval pathway.
FDA asks groups how it can help ensure prescribing is limited for products approved under proposed new pathway, but several say, other than labeling, it may be out of the agency’s hands.
The agency seeks input on which diseases, beyond drug-resistant infections, could benefit from rapid approval of therapies for subpopulations of patients; public hearing in February will ask how labeling should best express the limited indications.